does pfizer make semaglutide Phase IIb Data Support Monthly GLP-1 Dosing for Obesity Pfizer is pulling back the

SKU: 74488322443

Pay in 4 interest-free payments of $7.27 Learn more

Live Spec

Pfizer is pulling back the curtain on its obesity ambitions, releasing new data on an experimental weight loss shot and outlining a strategy to claw its way into a leadership position in the Pfizer's shares fell over 3% after trial data from its Metsera acquired obesity drug raised tolerability concerns. The monthly injection showed up to 12.3% weight loss at 28 weeks, but 10% dropped out Use of new diet drugs likely to mushroom Harvard Gazette Skinny jabs': weight loss drugs set for new boom as generic versions emerge Pharmaceuticals industry The Guardian

Store: gspetersdorf.de · Domain: gspetersdorf.de